
MetaVia Inc. (NASDAQ:MTVA – Free Report) – HC Wainwright issued their FY2026 earnings per share (EPS) estimates for shares of MetaVia in a note issued to investors on Tuesday, November 17th. HC Wainwright analyst A. Ghosh anticipates that the company will post earnings of ($3.07) per share for the year. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for MetaVia’s current full-year earnings is ($2.52) per share. HC Wainwright also issued estimates for MetaVia’s Q4 2026 earnings at ($0.72) EPS, FY2027 earnings at ($3.77) EPS, FY2028 earnings at ($2.28) EPS, FY2029 earnings at ($1.88) EPS and FY2030 earnings at ($1.58) EPS.
MetaVia (NASDAQ:MTVA – Get Free Report) last released its quarterly earnings results on Friday, November 13th. The company reported ($0.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.04.
View Our Latest Research Report on MTVA
MetaVia Price Performance
MetaVia stock opened at $1.01 on Thursday. The business’s fifty day moving average is $1.40 and its two-hundred day moving average is $1.58. MetaVia has a 52 week low of $0.97 and a 52 week high of $13.42.
About MetaVia
MetaVia, Inc. is a clinical-stage biotechnology company focused on developing treatments for cardiometabolic diseases, including obesity, metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes. The company’s pipeline includes DA-1726, an investigational dual GLP-1 and glucagon receptor agonist being studied for obesity, and DA-1241, an investigational GPR119 agonist being developed for MASH and type 2 diabetes. These candidates are experimental and have not been established as approved treatments.
Featured Articles
- Five stocks we like better than MetaVia
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.
